ANGN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jun 2023 @ 16:00):

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases...

Stats
Today's Volume	224 803
Average Volume	9 772.00
Market Cap	30.11M
EPS	$0 ( 2024-03-15 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0989
ATR14	$0.0950 (9.50%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Nissenson Allen	Buy	4 100	Stock Option (right to buy)
2023-12-28	Chudnovsky Yekaterina	Buy	4 100	Stock Option (right to buy)
2023-12-28	Wilson Karen J	Buy	4 100	Stock Option (right to buy)
2023-12-28	Adams Julian	Buy	4 100	Stock Option (right to buy)
2023-12-28	Venkatesan Jay	Buy	4 100	Stock Option (right to buy)

INSIDER POWER
56.30
Last 97 transactions
Buy: 4 979 407 \| Sell: 2 616 033

Volume Correlation

Long: 0.38 (neutral)

Short: 0.32 (neutral)

Signal:(71.808) Neutral

Angion Biomedica Corp. Correlation

10 Most Positive Correlations
MYSZ	0.924
SMFL	0.92
ALXO	0.915
IRBT	0.914
SSPK	0.913
TRIT	0.908
SPCX	0.905
VNDA	0.903
NCBS	0.903
MTP	0.902

10 Most Negative Correlations
CFFE	-0.929
ARIZ	-0.924
LRMR	-0.922
ROCL	-0.922
OTEC	-0.919
FICV	-0.916
OVLY	-0.915
AIB	-0.914
FATP	-0.914
EMLD	-0.914

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Angion Biomedica Corp. Correlation - Currency/Commodity

-0.16
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.50
( weak negative )

-0.77
( moderate negative )

0.58
( weak )

Angion Biomedica Corp. Financials

Annual	2022
Revenue:	$2.30M
Gross Profit:	$2.30M (100.00 %)
EPS:	$-1.850

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.270

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.44

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.150

Financial Reports:

No articles found.

Angion Biomedica Corp.

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.